SymbolADIA
NameADIA MED, INC.
SectorUNDEFINED
RegionNorth America
Industry-
Address32789 United States FL 1561 West Fairbanks Avenue Suite 205
Telephone(321) 788-0850
Fax
Email
Websitehttps://adiamed.com
IncorporationUS
Incorporated On1975
Employees
Fiscal Year12/31
Public Since
ExchangesOTC
AuditorHaynie & Company, CPA;H-Squared Ventures, LLC;
Audit StatusAUDITED
Reporting StatusU.S. Reporting: SEC Reporting
CIK0001160420
Description

Adia Med Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company dedicated to advancing regenerative medicine and healthcare innovation. The company operates through its primary divisions: Adia Med clinics and Adia Labs LLC. Adia Med clinics deliver specialized regenerative treatments, including stem cell therapies, platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT). The company actively conducts multiple Institutional Review Board (IRB)-approved clinical studies, including those targeting autism spectrum disorder, chronic kidney disease, and lower back pain, with plans to initiate additional studies in 2026. Through Adia Labs, the company manufactures and distributes high-quality regenerative products such as AdiaVita and AdiaLink. Revenue is generated through product sales, clinical service fees, insurance billing for eligible treatments, and equity investments. The company maintains an 18% equity stake in Cement Factory LLC, a nutrition and supplement company aligned with its health and wellness focus. It has also launched ADIA Life LLC to support broader distribution of wellness solutions. Through strategic partnerships with medical institutions and clinics, a strong commitment to rigorous clinical research, and adherence to standardized, compliant laboratory protocols, Adia Med Inc. is building a platform for growth in regenerative healthcare.

Additional info from OTC:
Adia Med Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company dedicated to advancing regenerative medicine and healthcare innovation. The company operates through its primary divisions: Adia Med clinics and Adia Labs LLC. Adia Med clinics deliver specialized regenerative treatments, including stem cell therapies, platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT). The company actively conducts multiple Institutional Review Board (IRB)-approved clinical studies, including those targeting autism spectrum disorder, chronic kidney disease, and lower back pain, with plans to initiate additional studies in 2026. Through Adia Labs, the company manufactures and distributes high-quality regenerative products such as AdiaVita and AdiaLink. Revenue is generated through product sales, clinical service fees, insurance billing for eligible treatments, and equity investments. The company maintains an 18% equity stake in Cement Factory LLC, a nutrition and supplement company aligned with its health and wellness focus. It has also launched ADIA Life LLC to support broader distribution of wellness solutions. Through strategic partnerships with medical institutions and clinics, a strong commitment to rigorous clinical research, and adherence to standardized, compliant laboratory protocols, Adia Med Inc. is building a platform for growth in regenerative healthcare.

No news found.